E
NextCure, Inc.
NXTC
$0.40
$0.01423.68%
E
Sell
3/14/2025Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 3/14/2025 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.4125 to -$0.4143.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 3/14/2025 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.4125 to -$0.4143.
D
Sell
3/4/2025Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 3/4/2025 due to an increase in the volatility index and growth index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 3/4/2025 due to an increase in the volatility index and growth index.
E
Sell
1/8/2025Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 1/8/2025 due to a decline in the total return index, volatility index and solvency index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 1/8/2025 due to a decline in the total return index, volatility index and solvency index.
D
Sell
11/4/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 11/4/2024 due to an increase in the total return index and volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 11/4/2024 due to an increase in the total return index and volatility index.
E
Sell
10/17/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 10/17/2024 due to a decline in the volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 10/17/2024 due to a decline in the volatility index.
D
Sell
9/27/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 9/27/2024 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 9/27/2024 due to an increase in the volatility index.
E
Sell
9/12/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 9/12/2024 due to a decline in the volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 9/12/2024 due to a decline in the volatility index.
D
Sell
8/22/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/22/2024 due to an increase in the volatility index and total return index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/22/2024 due to an increase in the volatility index and total return index.
E
Sell
8/7/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 8/7/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 10.08 to 8.03.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 8/7/2024 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 10.08 to 8.03.
D
Sell
7/18/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 7/18/2024 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 7/18/2024 due to an increase in the volatility index.
E
Sell
7/2/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 7/2/2024 due to a decline in the volatility index and total return index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 7/2/2024 due to a decline in the volatility index and total return index.
D
Sell
6/12/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 6/12/2024 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 6/12/2024 due to an increase in the volatility index.
E
Sell
5/24/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 5/24/2024 due to a decline in the volatility index and solvency index. The quick ratio declined from 15.85 to 10.08.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 5/24/2024 due to a decline in the volatility index and solvency index. The quick ratio declined from 15.85 to 10.08.
D
Sell
5/7/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index and total return index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/7/2024 due to an increase in the volatility index and total return index.
E
Sell
4/17/2024Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
D
Sell
4/2/2024Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 4/2/2024 due to a noticeable increase in the volatility index and total return index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 4/2/2024 due to a noticeable increase in the volatility index and total return index.
E
Sell
3/31/2023Upgraded
NextCure, Inc. (NXTC) was upgraded to E+ from E on 3/31/2023 due to an increase in the volatility index and total return index.
NextCure, Inc. (NXTC) was upgraded to E+ from E on 3/31/2023 due to an increase in the volatility index and total return index.
E
Sell
3/16/2023Downgrade
NextCure, Inc. (NXTC) was downgraded to E from E+ on 3/16/2023 due to a decline in the volatility index and total return index.
NextCure, Inc. (NXTC) was downgraded to E from E+ on 3/16/2023 due to a decline in the volatility index and total return index.
E
Sell
11/10/2022Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 11/10/2022 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 32.56 to 28.72, EBIT declined 6.13% from -$18.13M to -$19.24M, and earnings per share declined from -$0.65 to -$0.6815.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 11/10/2022 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 32.56 to 28.72, EBIT declined 6.13% from -$18.13M to -$19.24M, and earnings per share declined from -$0.65 to -$0.6815.
D
Sell
8/8/2022Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 12.72% from -$20.77M to -$18.13M, earnings per share increased from -$0.7435 to -$0.65, and operating cash flow increased 6.2% from -$15.45M to -$14.49M.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/8/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 12.72% from -$20.77M to -$18.13M, earnings per share increased from -$0.7435 to -$0.65, and operating cash flow increased 6.2% from -$15.45M to -$14.49M.
E
Sell
7/20/2022Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 7/20/2022 due to a decline in the volatility index and total return index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 7/20/2022 due to a decline in the volatility index and total return index.
D
Sell
7/5/2022Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 7/5/2022 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 7/5/2022 due to an increase in the volatility index.
E
Sell
6/15/2022Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 6/15/2022 due to a decline in the volatility index, total return index and valuation index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 6/15/2022 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/31/2022Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 33.23 to 31.34.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 33.23 to 31.34.
D
Sell
5/5/2022Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the solvency index and volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the solvency index and volatility index.
D
Sell
8/25/2021Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/25/2021 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/25/2021 due to an increase in the volatility index.
E
Sell
8/10/2021Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 8/10/2021 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 32.76 to 29.13.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 8/10/2021 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 32.76 to 29.13.
D
Sell
8/2/2021Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/2/2021 due to an increase in the volatility index and valuation index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 8/2/2021 due to an increase in the volatility index and valuation index.
E
Sell
6/28/2021Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 6/28/2021 due to a decline in the total return index and volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 6/28/2021 due to a decline in the total return index and volatility index.
D
Sell
5/10/2021Downgrade
NextCure, Inc. (NXTC) was downgraded to D- from D on 5/10/2021 due to a large decline in the growth index and volatility index. Operating cash flow declined 121.58% from -$6.28M to -$13.91M, earnings per share declined from -$0.5611 to -$0.6, and EBIT declined 6.14% from -$16.24M to -$17.23M.
NextCure, Inc. (NXTC) was downgraded to D- from D on 5/10/2021 due to a large decline in the growth index and volatility index. Operating cash flow declined 121.58% from -$6.28M to -$13.91M, earnings per share declined from -$0.5611 to -$0.6, and EBIT declined 6.14% from -$16.24M to -$17.23M.
D
Sell
11/9/2020Upgraded
NextCure, Inc. (NXTC) was upgraded to D from D- on 11/9/2020 due to a large increase in the growth index, total return index and valuation index.
NextCure, Inc. (NXTC) was upgraded to D from D- on 11/9/2020 due to a large increase in the growth index, total return index and valuation index.
D
Sell
11/5/2020Upgraded
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 11/5/2020 due to an increase in the volatility index.
NextCure, Inc. (NXTC) was upgraded to D- from E+ on 11/5/2020 due to an increase in the volatility index.
E
Sell
9/8/2020Downgrade
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 9/8/2020 due to a large decline in the total return index and volatility index.
NextCure, Inc. (NXTC) was downgraded to E+ from D- on 9/8/2020 due to a large decline in the total return index and volatility index.
D
Sell
8/10/2020Downgrade
NextCure, Inc. (NXTC) was downgraded to D- from D on 8/10/2020 due to a substantial decline in the growth index, efficiency index and volatility index. EBIT declined 292.41% from $8.21M to -$15.8M, earnings per share declined from $0.33 to -$0.5272, and net income declined 249.06% from $9.73M to -$14.51M.
NextCure, Inc. (NXTC) was downgraded to D- from D on 8/10/2020 due to a substantial decline in the growth index, efficiency index and volatility index. EBIT declined 292.41% from $8.21M to -$15.8M, earnings per share declined from $0.33 to -$0.5272, and net income declined 249.06% from $9.73M to -$14.51M.
D
Sell
11/5/2019Upgraded
NextCure, Inc. (NXTC) was upgraded to D from E on 11/5/2019 due to a noticeable increase in the total return index.
NextCure, Inc. (NXTC) was upgraded to D from E on 11/5/2019 due to a noticeable increase in the total return index.
E
Sell
8/19/2019Upgraded
NextCure, Inc. (NXTC) was upgraded to E from E- on 8/19/2019 due to a large increase in the solvency index, growth index and valuation index.
NextCure, Inc. (NXTC) was upgraded to E from E- on 8/19/2019 due to a large increase in the solvency index, growth index and valuation index.
E
Sell
8/13/2019None
NextCure, Inc. (NXTC) was downgraded to E- from U on 08/13/2019.
NextCure, Inc. (NXTC) was downgraded to E- from U on 08/13/2019.
NASDAQ
04/08/2025 10:50AM Eastern
Quotes delayed
